Biomarker discovery, genotoxicity and editing

KromaTiD specializes in advanced genomic analysis technologies that are crucial for the development of cell and gene therapies. Their proprietary directional Genomic Hybridization (dGH™) platform allows for the direct visualization of both intended and unintended genome modifications, providing critical insights into genomic integrity. This technology is complemented by their custom karyotyping services, including G-banding and genomic integrity karyotyping, which offer detailed analysis and comparison reporting for donor and treated cells. KromaTiD's focus on structural genomic integrity analysis enables researchers and developers to de-risk their therapy programs, ensuring a better understanding of genomic changes throughout the product lifecycle.

In addition to their dGH™ platform, KromaTiD offers a range of services designed to support Investigational New Drug (IND) submissions, including IND Enabling Packages that provide robust data and customized reporting. Their capabilities extend to pivotal batch analysis, structural variant evaluation, and genomic integrity testing, all aimed at optimizing genome editing approaches and ensuring the quality control of cell and gene therapies. By leveraging these technologies, KromaTiD is committed to advancing the development of life-changing therapies, facilitating a smoother transition from research to clinical application.

United States

KromaTiD, Inc. provides products and services for mutation detection and disease diagnosis. KromaTiD’s patented dGH™ chromosome imaging platform enables detection of all types of chromosomal rearrangements including previously undetectable cryptic inversions.

KromaTiD

Company Details